Argenx Se (ARGX) Net Margin (2016 - 2026)
Argenx Se (ARGX) posted quarterly Net Margin of 30.33% for Q2 2026, up 447.0% year-on-year from 5.55% in Q2 2025, and up 7.58% on a QoQ basis from 28.2% in Q1 2026.
Argenx Se (ARGX) Net Margin (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Net Margin for 11 consecutive years, with 30.33% the latest figure, recorded in Q2 2026.
- Quarterly Net Margin rose 447.0% year-over-year to 30.33% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 32.57% (down 942.0% YoY) and the FY2025 annual result came in at 30.41%, down 658.0% from the prior year.
- Net Margin climbed to 30.33% in Q2 2026 per ARGX's latest filing, from 28.2% in the prior quarter.
- Over the last five years, Net Margin for ARGX reached as high as 886.14% in Q2 2022 and fell as low as 1073.51% in Q1 2022.
- A 5-year average of 10.47% and a median of 18.67% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin tumbled 110012 bps — and 2023, when it jumped 108675 bps.
- Year by year, Net Margin stood at 22.27% in 2022, then slipped by 19 bps to 26.49% in 2023, then jumped by 497 bps to 105.05% in 2024, then tumbled by 61 bps to 41.45% in 2025, then dropped by 27 bps to 30.33% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 30.33%, 28.2%, and 41.45% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 17.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.33% |
| Mar 31, 2026 | 28.20% |
| Dec 31, 2025 | 41.45% |
| Sep 30, 2025 | 30.55% |
| Jun 30, 2025 | 25.87% |
| Mar 31, 2025 | 21.39% |
| Dec 31, 2024 | 105.05% |
| Sep 30, 2024 | 15.95% |
| Jun 30, 2024 | 6.09% |
| Mar 31, 2024 | -15.47% |
| Dec 31, 2023 | -26.49% |
| Sep 30, 2023 | -22.07% |
| Jun 30, 2023 | -35.04% |
| Mar 31, 2023 | 13.24% |
| Dec 31, 2022 | -22.27% |
| Sep 30, 2022 | 178.97% |
| Jun 30, 2022 | 886.14% |
| Mar 31, 2022 | -1,073.51% |
| Dec 31, 2021 | -913.91% |
| Sep 30, 2021 | -0.03% |